




Instance: composition-en-5c60b262e52a5c74cf3187377ecaedde
InstanceOf: CompositionUvEpi
Title: "Composition for teriflunomide Package Leaflet"
Description:  "Composition for teriflunomide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa06655ee7cdbd14126a29be1f113931d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - teriflunomide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Teriflunomide Accord is and what it is used for  </li>
<li>What you need to know before you take Teriflunomide Accord  </li>
<li>How to take Teriflunomide Accord  </li>
<li>Possible side effects  </li>
<li>How to store Teriflunomide Accord  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What teriflunomide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What teriflunomide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Teriflunomide Accord is 
Teriflunomide Accord contains the active substance teriflunomide which is an immunomodulatory agent and 
adjusts the immune system to limit its attack on the nervous system. </p>
<p>What Teriflunomide Accord is used for 
Teriflunomide Accord is used in adults and in children and adolescents (10 years of age and older) to treat 
relapsing remitting multiple sclerosis (MS). </p>
<p>What multiple sclerosis is 
MS is a long-term illness that affects the central nervous system (CNS). The CNS is made up of the brain 
and spinal cord. In multiple sclerosis, inflammation destroys the protective sheath (called myelin) around the 
nerves in the CNS. This loss of myelin is called demyelination. This stops nerves from working properly. </p>
<p>People with relapsing form of multiple sclerosis will have repeated attacks (relapses) of physical symptoms 
caused by their nerves not working properly. These symptoms vary from patient to patient but usually 
involve: 
* difficulty walking 
* vision problems 
* balance problems. </p>
<p>Symptoms may disappear completely after the relapse is over, but over time, some problems may remain 
between relapses. This can cause physical disabilities that may interfere with your daily activities. </p>
<p>How Teriflunomide Accord works 
Teriflunomide Accord helps to protect against attacks on the central nervous system by the immune system 
by limiting the increase of some white blood cells (lymphocytes). This limits the inflammation that leads to 
nerve damage in MS. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Teriflunomide Accord:</p>
<ul>
<li>if you are allergic to teriflunomide or any of the other ingredients of this medicine (listed in section 6), </li>
<li>if you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after 
taking teriflunomide or leflunomide, </li>
<li>if you have severe liver problems, </li>
<li>if you are pregnant, think you may be pregnant, or are breast-feeding, </li>
<li>if you suffer from a serious problem which affects your immune system e.g. acquired 
immunodeficiency syndrome (AIDS), </li>
<li>if you have a serious problem with your bone marrow, or if you have low numbers of red or white 
cells in your blood or a reduced number of blood platelets, </li>
<li>if you are suffering from a serious infection, </li>
<li>if you have severe kidney problems which require dialysis, </li>
<li>if you have very low levels of proteins in your blood (hypoproteinaemia), </li>
</ul>
<p>If you are not sure, talk to your doctor or pharmacist before taking this medicine. </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Teriflunomide Accord if:</p>
<ul>
<li>you have liver problems and/or if you drink large amounts of alcohol. Your doctor will carry out blood 
tests before and during treatment to check how well your liver is working. If your test results show a 
problem with your liver, your doctor may stop your treatment with Teriflunomide Accord. Please read 
section 4. - you have high blood pressure (hypertension) whether it is controlled with medicines or not. 
Teriflunomide Accord can cause an increase in blood pressure. Your doctor will check your blood 
pressure before the start of treatment and regularly thereafter. Please read section 4. - you have an infection. Before you take Teriflunomide Accord, your doctor will make sure you have 
enough white blood cells and platelets in your blood. As Teriflunomide Accord decreases the number 
of white cells in the blood this may affect your ability to fight the infection. Your doctor may do blood 
tests to check your white blood cells if you think you have an infection. Please read section 4. - you have severe skin reactions. </li>
<li>you have respiratory symptoms. </li>
<li>you have weakness, numbness and pain in the hands and feet. </li>
<li>you are going to have a vaccination. </li>
<li>you take leflunomide with Teriflunomide Accord. </li>
<li>you are switching to or from Teriflunomide Accord. </li>
<li>you are due to have a specific blood test (calcium level). Falsely low levels of calcium can be detected. </li>
</ul>
<p>Respiratory reactions 
Tell your doctor if you have unexplained cough and dyspnoea (shortness of breath). Your doctor may 
perform additional tests </p>
<p>Children and adolescents 
Teriflunomide Accord is not intended for use in children under 10 years of age, as it has not been studied in 
MS patients in this age group.<br />
The warnings and precautions listed above also apply to children. The following information is important for 
children and their caregivers:</p>
<ul>
<li>inflammation of the pancreas has been observed in patients receiving teriflunomide. Your child s 
doctor may carry out blood tests if an inflammation to the pancreas is suspected.  </li>
</ul>
<p>Other medicines and Teriflunomide Accord 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This 
includes medicines obtained without a prescription. 
In particular, tell your doctor or pharmacist if you are taking any of the following:</p>
<ul>
<li>leflunomide, methotrexate and other medicines that affect the immune system (often called 
immunosuppressants or immunomodulators) </li>
<li>rifampicin (a medicine used to treat tuberculosis and other infections) </li>
<li>carbamazepine, phenobarbital, phenytoin for epilepsy </li>
<li>St John s wort (a herbal medicine for depression) </li>
<li>repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes </li>
<li>daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer </li>
<li>duloxetine for depression, urinary incontinenece or in kidney disease in diabetics </li>
<li>alosetron for the management of severe diarrhoea </li>
<li>theophylline for asthma </li>
<li>tizanidine, a muscle relaxant </li>
<li>warfarin, an anticoagulant used to make the blood thinner (i.e. more fluid) in order to avoid blood clots </li>
<li>oral contraceptives (containing ethinylestradiol and levonorgestrel) </li>
<li>cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections </li>
<li>indometacin, ketoprofen for pain or inflammation </li>
<li>furosemide for heart disease </li>
<li>cimetidine for reducing gastric acid </li>
<li>zidovudine for HIV infection </li>
<li>rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol) </li>
<li>sulfasalazine for inflammatory bowel disease or rheumatoid arthritis </li>
<li>cholestyramine for high cholesterol or relief from itching in liver disease </li>
<li>activated charcoal to reduce absorption of medicines or other substances </li>
</ul>
<p>Pregnancy and breast-feeding 
Do not take Teriflunomide Accord if you are or think you may be pregnant. If you are pregnant or become 
pregnant while taking Teriflunomide Accord, the risk of having a baby with birth defects is increased. 
Women of childbearing potential must not take this medicine without using reliable contraceptive measures. 
If your daughter reaches menses while taking Teriflunomide Accord, you should inform the doctor, who will 
provide specialist counselling regarding contraception and the potential risks in case of pregnancy.  </p>
<p>Tell your doctor if you plan to become pregnant after stopping treatment with Teriflunomide Accord, as 
you need to ensure that most of this medicine has left your body before trying to become pregnant. The 
elimination of the active substance may take up to 2 years to occur naturally. The time can be reduced to a 
few weeks by taking certain medicines which speed up removal of teriflunomide from your body.<br />
In either case it should be confirmed by a blood test that the active substance has been sufficiently removed 
from your body and you need confirmation from your treating physician that the blood level of teriflunomide 
is low enough to allow you to become pregnant. </p>
<p>For further information on the laboratory testing please contact your doctor. </p>
<p>If you suspect that you are pregnant while taking Teriflunomide Accord or in the two years after you have 
stopped treatment, you must discontinue Teriflunomide Accord and contact your doctor immediately for a 
pregnancy test. If the test confirms that you are pregnant, your doctor may suggest treatment with certain 
medicines to remove teriflunomide rapidly and sufficiently from your body, as this may decrease the risk to 
your baby. </p>
<p>Contraception 
You must use an effective method of contraception during and after treatment with Teriflunomide Accord. 
Teriflunomide remains in your blood for a long time after you stop taking it. Continue to use effective 
contraception after you stop treatment. 
- Do this until the levels of teriflunomide in your blood are low enough - your doctor will check this. 
- Talk with your doctor about the best method of contraception for you and any potential need for 
contraception change. </p>
<p>Do not take Teriflunomide Accord when you are breast-feeding, as teriflunomide passes into the breast milk. </p>
<p>Driving and using machines 
Teriflunomide Accord might make you feel dizzy which may impair your ability to concentrate and react. If 
you are affected, do not drive or use machines. </p>
<p>Teriflunomide Accord contains lactose 
Teriflunomide Accord contains lactose (a type of sugar). If you have been told by your doctor that you have 
an intolerance to some sugars, contact your doctor before taking this medicine.<br />
Teriflunomide Accord contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Treatment with Teriflunomide Accord will be overseen by a doctor who is experienced in the treatment of 
multiple sclerosis. </p>
<p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. </p>
<p>Adults 
The recommended dose is one 14 mg  tablet daily. </p>
<p>Children and adolescents (10 years of age and above) 
The dose depends on body weight:</p>
<ul>
<li>Children with body weight greater than 40 kg: one 14 mg tablet daily.  </li>
<li>Children with body weight less than or equal to 40 kg: one 7 mg tablet daily. </li>
</ul>
<p>7 mg tablets are not available under this tradename and another medicine with teriflunomide should be taken 
in this case. </p>
<p>Children and adolescents who reach a stable body weight above 40 kg will be instructed by their doctor to 
switch to one 14 mg tablet daily. </p>
<p>Route/method of administration 
Teriflunomide Accord is for oral use. Teriflunomide Accord is taken every day as a single dose at any time 
of the day. 
You should swallow the tablet whole with some water. 
Teriflunomide Accord may be taken with or without food. </p>
<p>If you take more Teriflunomide Accord than you should 
If you have taken too much Teriflunomide Accord, call your doctor straight away. You may experience side 
effects similar to those described in section 4 below. </p>
<p>If you forget to take Teriflunomide Accord 
Do not take a double dose to make up for a forgotten tablet. Take your next dose at the scheduled time. </p>
<p>If you stop taking Teriflunomide Accord 
Do not stop taking Teriflunomide Accord or change your dose without talking to your doctor first. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
The following side effects may happen with this medicine. </p>
<p>Serious side effects </p>
<p>Some side effects could be or could become serious, if you experience any of these, tell your doctor 
immediately. </p>
<p>Common (may affect up to 1 in 10 people) 
- inflammation of the pancreas which might include symptoms of pain in the abdominal area, nausea, or 
vomiting (the frequency is common in paediatric patients and uncommon in adult patients). </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- allergic reactions which might include symptoms of rash, hives, swelling of lips, tongue or face or 
sudden difficulty breathing. 
- severe skin reactions which might include symptoms of skin rash, blistering, fever, or ulcers in your 
mouth. 
- severe infections or sepsis (a potentially life-threatening type of infection) which might include 
symptoms of high fever, shaking, chills, reduced urine flow, or confusion. 
- inflammation of the lungs which might include symptoms of shortness of breath or persistent cough. </p>
<p>Not known (frequency cannot be estimated from the available data):</p>
<ul>
<li>serious liver disease which might include symptoms of yellowing of your skin or the whites of your 
eyes, darker urine than normal, unexplained nausea and vomiting, or abdominal pain.  </li>
</ul>
<p>Other side effects can occur with the following frequencies: </p>
<p>Very common (may affect more than 1 in 10 people) 
- Headache 
- Diarrhoea, feeling sick 
- Increase in ALT (increase in blood levels of certain hepatic enzymes) shown in tests 
- Hair thinning. </p>
<p>Common (may affect up to 1 in 10 people) 
- Influenza, upper respiratory tract infection, urinary tract infection, bronchitis, sinusitis, sore throat and 
discomfort when swallowing, cystitis, gastroenteritis viral, oral herpes, tooth infection, laryngitis, 
fungal infection of the foot 
- Laboratory values: a decrease in the number of red blood cells (anaemia), changes in liver and white 
blood cell test results (see section 2), as well as elevations in a muscle enzyme (creatine 
phosphokinase) have been observed. 
- Mild allergic reactions 
- Feeling anxious 
- Pins and needles, feeling weak, numb, tingling or pain in the lower back or leg (sciatica); feeling 
numb, burning, tingling or pain in the hands and fingers (carpal tunnel syndrome) 
- Feeling your heartbeat 
- Increase in blood pressure 
- Being sick (vomiting), toothache, upper abdominal pain 
- Rash, acne 
- Pain of the tendons, joints, bones, muscle pain (musculoskeletal pain), 
- Needing to urinate more often than usual 
- Heavy periods 
- Pain 
- Lack of energy or feeling weak (asthenia). 
- Weight loss </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- Decrease in the number of blood platelets (mild thrombocytopenia) 
- Increased feeling or sensitivity, especially in the skin; stabbing or throbbing pain along one or more 
nerves, problems in the nerves of the arms or legs (peripheral neuropathy) 
- Nail disorders, severe skin reactions 
- Post-traumatic pain 
- Psoriasis 
- Inflammation of mouth/lips 
- Abnormal levels of fats (lipids) in the blood 
- Inflammation of the colon (colitis). </p>
<p>Rare (may affect up to 1 in 1,000 people) 
- Inflammation or injury of the liver. </p>
<p>Not known (frequency cannot be estimated from the available data) 
- Respiratory hypertension. </p>
<p>Children (10 years of age and above) and adolescents 
The side effects listed above also apply to children and adolescents. The following additional information is 
important for children, adolescents, and their caregivers: </p>
<p>Common (may affect up to 1 in 10 people) 
- Inflammation of the pancreas </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed 
in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix 
V. By reporting side effects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton after  EXP . The expiry date 
refers to the last day of that month. </p>
<p>This medicinal product does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Teriflunomide Accord contains 
- The active substance is teriflunomide. Each tablet contains14 mg of teriflunomide. 
- The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, sodium starch 
glycolate, hydroxypropylcellulose, magnesium stearate, colloidal anhydrous silica, hypromellose 
(E464), titanium dioxide (E171), talc (E553b), macrogol (E1521), indigo carmine aluminum lake 
(E132). </p>
<p>What Teriflunomide Accord looks like and contents of the pack 
Teriflunomide Accord 14 mg film-coated tablets (tablets) are blue colored, pentagonal shaped, film coated 
tablets, debossed with  T2  on one side and plain on other side. </p>
<p>Teriflunomide Accord is available in cartons containing:</p>
<ul>
<li>28 and 84 tablets in aluminium-aluminium blisters; </li>
<li>28x1 and 84x1 tablet in aluminium-aluminium perforated unit-dose blisters. </li>
</ul>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Accord Healthcare S.L.U. 
World Trade Center,<br />
Moll De Barcelona s/n,<br />
Edifici Est, 6a Planta,<br />
Barcelona, 08039, Spain 
Manufacturer 
Accord Healthcare Polska Sp. z.o.o. 
ul.Lutomierska 50, 
95-200, Pabianice, Poland </p>
<p>Accord Healthcare B.V. 
Winthontlaan 200,<br />
3526 KV Utrecht, Netherlands </p>
<p>Pharmadox Healthcare Ltd. 
KW20A Kordin Industrial Park, 
Paola PLA 3000, Malta </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-5c60b262e52a5c74cf3187377ecaedde
InstanceOf: CompositionUvEpi
Title: "Composition for teriflunomide Package Leaflet"
Description:  "Composition for teriflunomide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa06655ee7cdbd14126a29be1f113931d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - teriflunomide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Teriflunomide Accord 
3. Sådan skal du tage Teriflunomide Accord<br />
4. Bivirkninger<br />
5. Opbevaring<br />
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What teriflunomide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What teriflunomide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Teriflunomide Accord indeholder det aktive stof teriflunomid, som er et immunmodulerende middel, 
der justerer immunsystemet til at begrænse sit angreb på nervesystemet. </p>
<p>Anvendelse 
Teriflunomide Accord anvendes til behandling af voksne, børn og unge (10 år og derover) med 
attakvis multipel sklerose (MS). </p>
<p>Hvad er multipel sclerose 
MS er en kronisk sygdom, der påvirker centralnervesystemet. Centralnervesystemet består af hjernen 
og rygmarven. Ved multipel sklerose ødelægger betændelse den beskyttende kappe (kaldet myelin), 
som ligger omkring nerverne i centralnervesystemet, hvilket forhindrer nerverne i at fungere normalt.  </p>
<p>Personer, der lider af attakvis multipel sklerose, oplever gentagne anfald (attakker) med fysiske 
symptomer, der skyldes, at nerverne ikke fungerer, som de skal. Disse symptomer varierer fra patient 
til patient, men omfatter normalt: 
 
gangbesvær 
 
synsproblemer 
 
balanceproblemer. </p>
<p>Symptomerne kan forsvinde fuldstændigt, når attakket er ovre, men med tiden kan nogle af 
problemerne fortsætte mellem attakkerne. Dette kan medføre nedsat fysisk funktion, der kan gribe 
forstyrrende ind i dagligdagens aktiviteter. </p>
<p>Hvordan Teriflunomide Accord virker 
Teriflunomide Accord hjælper med at beskytte mod attakker på centralnervesystemet fra 
immunsystemet og ved at begrænse stigningen i visse hvide blodlegemer (lymfocytter). Dette 
begrænser samtidig betændelsen, som leder til nervebeskadigelse ved MS.   </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Teriflunomide Accord:</p>
<ul>
<li>hvis du er allergisk over for teriflunomid eller et af de øvrige indholdsstoffer i Teriflunomide 
Accord (angivet i punkt 6) </li>
<li>hvis du nogensinde har udviklet alvorligt hududslæt eller hudafskalning, blisterdannelse og/eller 
sår i munden efter at have taget teriflunomid eller leflunomid </li>
<li>hvis du har en alvorlig leversygdom </li>
<li>hvis du er gravid, tror, du kan være gravid, eller ammer </li>
<li>hvis du har alvorlige sygdomme, der påvirker immunsystemet f.eks. erhvervet immundefekt 
syndrom (AIDS) </li>
<li>hvis du har alvorlige problemer med rygmarven, eller hvis du har et lavt antal røde eller hvide 
blodlegemer eller et nedsat antal blodplader </li>
<li>hvis du lider af en alvorlig infektion </li>
<li>hvis du har en alvorlig nyresygdom, som kræver dialyse </li>
<li>hvis du har en meget lav koncentration af proteiner i blodet (hypoproteinæmi) 
Spørg lægen eller apotekspersonalet, før du tager dette lægemiddel, hvis der er noget, du er i tvivl om. </li>
</ul>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller apotekspersonalet, før du tager Teriflunomide Accord:</p>
<ul>
<li>hvis du har leverproblemer og/eller indtager store mængder alkohol. Din læge vil muligvis tage 
blodprøver før og under behandlingen for at kontrollere, hvor godt din lever fungerer. Hvis dine 
blodprøver viser, at der er et problem med din lever, vil lægen muligvis standse behandlingen 
med Teriflunomide Accord. Læs oplysningerne under punkt 4. - hvis du har forhøjet blodtryk (hypertension), uanset om dette behandles med medicin eller ej. 
Teriflunomid kan forårsage en stigning i blodtrykket. Lægen vil tjekke dit blodtryk før 
behandlingsstart og regelmæssigt derefter. Læs oplysningerne under punkt 4. - hvis du har en infektion. Før du tager Teriflunomide Accord, vil lægen kontrollere, at du har et 
tilstrækkeligt antal hvide blodlegemer og blodplader i blodet. Da teriflunomid nedsætter antallet 
af hvide blodlegemer i blodet, kan det have betydning for bekæmpelse af infektionen. Hvis du 
tror, du har en infektion, vil lægen muligvis tage blodprøver for at kontrollere de hvide 
blodlegemer. Læs oplysningerne under punkt 4. - hvis du har svære hudreaktioner. </li>
<li>hvis du har åndedrætssymptomer. </li>
<li>hvis du har svaghed, følelsesløshed og smerte i hænder og fødder. </li>
<li>hvis du skal vaccineres. </li>
<li>hvis du tager leflunomid sammen med Teriflunomide Accord. </li>
<li>hvis du skifter til eller fra Teriflunomide Accord. </li>
<li>hvis du skal have taget en særlig blodprøve (calciumniveau). Målingen kan vise fejlagtige lave 
calciumniveauer. </li>
</ul>
<p>Åndedrætsreaktioner 
Fortæl det til din læge, hvis du har uforklarlig hoste og åndenød. Din læge kan foretage yderligere 
tests. </p>
<p>Børn og unge 
Teriflunomide Accord må ikke anvendes til børn under 10 år, da det ikke er blevet undersøgt hos MS-
patienter i denne aldersgruppe.<br />
Ovenstående advarsler og forsigtighedsregler gælder også for børn. Følgende oplysninger er vigtige 
for børn og deres omsorgspersoner:</p>
<ul>
<li>der er set betændelse i bugspytkirtlen hos patienter, der får teriflunomid. Dit barns læge vil 
muligvis tage blodprøver, hvis der er mistanke om betændelse i bugspytkirtlen.  </li>
</ul>
<p>Brug af anden medicin sammen med Teriflunomide Accord  </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke er købt på 
recept. 
Du skal især fortælle det til lægen eller på apoteket, hvis du tager nogle af følgende:</p>
<ul>
<li>leflunomid, methotrexat eller andre lægemidler, der påvirker immunsystemet (ofte kaldet 
immununsuppressiva eller immunmodulatorer) </li>
<li>rifampicin mod tuberkulose og andre infektioner </li>
<li>carbamazepin, phenobarbital, phenytoin mod epilepsi </li>
<li>perikon - et naturlægemiddel mod depression </li>
<li>repaglinid, pioglitazon, nateglinid eller rosiglitazon mod sukkersyge </li>
<li>daunorubicin, doxorubicin, paclitaxel eller topotecan mod kræft </li>
<li>duloxetin mod depression, ufrivillig vandladning (urininkontinens) eller nyresygdom ved 
sukkersyge </li>
<li>alosetron til behandling af kraftig diarre </li>
<li>theophyllin mod astma </li>
<li>tizanidin, der virker muskelafslappende </li>
<li>warfarin, et såkaldt antikoagulerende middel, der bruges til at gøre blodet mere tyndtflydende 
(dvs. tyndere) for at undgå blodpropper </li>
<li>p-piller (indeholdende ethinylestradiol og levonorgestrel) </li>
<li>cefaclor, benzylpenicillin eller ciprofloxacin mod infektioner </li>
<li>indomethacin eller ketoprofen mod smerter eller gigt </li>
<li>furosemid mod hjertelidelser </li>
<li>cimetidin for at nedsætte produktionen af mavesyre </li>
<li>zidovudin mod hiv </li>
<li>rosuvastin, simvastatin, atorvastatin, pravastatin mod forhøjet kolesterol (hyperkolesterolæmi) </li>
<li>sulfasalazin mod inflammatorisk tarmsygdom eller leddegigt (reumatoid artrit) </li>
<li>colestyramin mod forhøjet kolesterol eller mod kløe ved leversygdom </li>
<li>aktivt kul for at reducere optagelsen af medicin eller andre stoffer  </li>
</ul>
<p>Graviditet og amning<br />
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager Teriflunomide Accord.<br />
Du må ikke tage Teriflunomide Accord, hvis du er eller tror, at du måske er gravid. Hvis du er gravid 
eller bliver gravid, mens du tager Teriflunomide Accord, er der en øget risiko for, at dit barn kan tage 
skade. Kvinder i den fødedygtige alder må kun tage dette lægemiddel, hvis de bruger en effektiv 
præventionsmetode. 
Hvis din datter får sin første menstruation under behandlingen med Teriflunomide Accord skal du 
informere lægen, som vil give specialvejledning vedrørende prævention og de mulige risici i tilfælde 
af graviditet. </p>
<p>Fortæl det til din læge, hvis du planlægger at blive gravid efter behandlingen med Teriflunomide 
Accord. Det er vigtigt at sikre, at indholdet af dette lægemiddel i blodet er tilstrækkeligt lavt, før du 
forsøger at blive gravid. Den normale udskillelse af det aktive stof kan vare op til 2 år, men tiden kan 
reduceres til nogle få uger ved at tage visse bestemte lægemidler, som øger den hastighed, hvormed 
teriflunomid udskilles fra kroppen. 
I alle tilfælde skal der tages en blodprøve for at bekræfte, at det aktive stof i tilstrækkelig grad er 
fjernet fra kroppen, og du skal have en bekræftelse fra din læge på, at koncentrationen af teriflunomid i 
blodet er lav nok til, at du kan forsøge at blive gravid. </p>
<p>Spørg lægen, hvis du vil have yderligere oplysninger om laboratorieprøverne. </p>
<p>Hvis du har mistanke om, at du er blevet gravid, mens du tager Teriflunomide Accord eller i en 
periode på to år efter, du har stoppet behandlingen, skal du straks stoppe med at tage Teriflunomide 
Accord og henvende dig til din læge med henblik på at få lavet en graviditetstest. Hvis denne test 
bekræfter, at du er gravid, vil din læge muligvis foreslå en behandling med visse lægemidler, der kan 
sikre en hurtig og tilstrækkelig fjernelse af teriflunomid fra din krop, da dette kan nedsætte risikoen for 
dit barn. </p>
<p>Prævention 
Du skal anvende en sikker præventionsmetode under og efter behandling med Teriflunomide Accord. 
Teriflunomid forbliver i blodet længe efter, at du er holdt op med at tage det. Bliv ved med at bruge 
sikker prævention, efter du har afsluttet behandlingen. 
- Du skal fortsætte med dette, indtil koncentrationen af teriflunomid i blodet er tilstrækkeligt lav - din læge vil kontrollere dette. 
- Tal med din læge om, hvilken præventionsmetode der passer bedst til dig og muligheden for at 
skifte til en anden præventionsmetode, hvis der er behov for dette. </p>
<p>Du må ikke tage Teriflunomide Accord, når du ammer, da teriflunomid udskilles i mælken. </p>
<p>Trafik- og arbejdssikkerhed 
Teriflunomide Accord kan medføre svimmelhed, hvilket kan svække din evne til at reagere og 
koncentrere sig. Hvis dette sker for dig, må du ikke føre motorkøretøj eller betjene maskiner. </p>
<p>Teriflunomide Accord indeholder lactose 
Teriflunomide Accord indeholder lactose (en type sukker). Kontakt lægen, for du tager dette 
lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter. </p>
<p>Teriflunomide Accord indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Behandlingen med Teriflunomide Accord vil blive styret af en læge, der har erfaring med behandling 
af multipel sklerose. </p>
<p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. </p>
<p>Voksne 
Den anbefalede dosis er 1 tablet på 14 mg dagligt.  </p>
<p>Børn og unge (10 år og derover)<br />
Dosis afhænger af kropsvægten:</p>
<ul>
<li>Børn, der vejer over 40 kg: 1 tablet på 14 mg dagligt.  </li>
<li>Børn, der vejer 40 kg eller derunder: 1 tablet på 7 mg dagligt.  </li>
</ul>
<p>Hos børn og unge, der når en stabil kropsvægt på over 40 kg, vil lægen ændre dosis til 1 tablet på 
14 mg dagligt. </p>
<p>Anvendelsesmåde 
Teriflunomide Accord er beregnet til at blive taget gennem munden (oral anvendelse). Du skal tage 
Teriflunomide Accord hver dag som en enkelt dosis. Du kan tage Teriflunomide Accord når som helst 
i løbet af dagen.<br />
Du skal synke tabletten hel med lidt vand. 
Teriflunomide Accord kan tages med eller uden mad. </p>
<p>Hvis du har taget for meget Teriflunomide Accord 
Hvis du har taget for meget Teriflunomide Accord, skal du straks kontakte lægen. Du kan få 
bivirkninger svarende til de bivirkninger, der er beskrevet i punkt 4. Hvis du har glemt at tage Teriflunomide Accord<br />
Du må ikke tage en dobbeltdosis som erstatning for en glemt tablet. Tag den næste dosis som planlagt. </p>
<p>Hvis du holder op med at tage Teriflunomide Accord  </p>
<p>Du må ikke stoppe med at tage Teriflunomide Accord eller ændre dosis uden først at tale med din 
læge. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Følgende bivirkninger kan forekomme med dette lægemiddel: </p>
<p>Alvorlige bivirkninger 
Nogle bivirkninger kan være eller blive alvorlige. Fortæl det omgående til lægen, hvis du bemærker 
nogle af følgende alvorlige bivirkninger. </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 patienter) 
- Betændelse i bugspytkirtlen, der kan have symptomer såsom smerter i maveregionen, kvalme 
eller opkastning (hyppigheden er almindelig hos pædiatriske patienter og ikke almindelig hos 
voksne patienter). </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter) 
- Allergiske reaktioner der kan have symptomer som udslæt, nældefeber, hævede læber, tunge 
eller ansigt eller pludseligt åndedrætsbesvær. 
- Alvorlige hudreaktioner der kan inkludere symptomer som hududslæt, blisterdannelse, feber 
eller sår i munden. 
- Alvorlige infektioner eller sepsis (en potentielt livstruende type infektion) der kan have 
symptomer som høj feber, rysten, kuldegysninger, reduceret urindannelse eller konfusion 
- Lungebetændelse der kan have symptomer som åndenød eller vedvarende hoste </p>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data) 
- Alvorlig leversygdom der kan have symptomer som gulfarvning af huden samt det hvide i 
øjnene, urin, der er mørkere end normalt, uforklarlig kvalme og opkastning eller mavesmerter </p>
<p>Andre bivirkninger kan forekomme med følgende hyppigheder: </p>
<p>Meget almindelige (kan forekomme hos flere end 1 ud af 10 patienter) 
- Hovedpine 
- Diarre, kvalme 
- Forhøjet ALAT (en stigning i blodets indhold af visse leverenzymer) påvist ved hjælp af en 
blodprøve 
- Udtynding af håret </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 patienter) 
- Influenza, infektion i de øvre luftveje, urinvejsinfektion, bronkitis, bihulebetændelse, ondt i 
halsen og ubehag, når der skal synkes, blærebetændelse, mave-tarminfektion forårsaget af virus, 
forkølelsessår, tandinfektion, strubekatar, fodsvamp 
- Laboratorieværdier: Et nedsat antal røde blodlegemer (anæmi), ændring i testresultater for lever 
og hvide blodlegemer (se pkt. 2), samt forhøjelse af et muskelenzym (kreatin fosfokinase) er 
blevet observeret. 
- Lette allergiske reaktioner 
- Angstfølelse 
- Prikkende, snurrende fornemmelse i huden, følelse af svaghed, følelsesløshed, snurrende 
fornemmelse eller smerter over lænden (iskias), følelsesløse, brændende, prikkende eller 
smertende hænder og fingre (karpaltunnelsyndrom) 
- Følelse af hjertebanken 
- Forhøjet blodtryk 
- Opkastning, tandpine, smerter i den øverste del af maven </p>
<ul>
<li>Udslæt, akne </li>
<li>Smerter i sener, led, knogler eller muskler  </li>
<li>Hyppigere vandladning </li>
<li>Kraftig menstruation </li>
<li>Smerter </li>
<li>Manglende energi eller følelse af kraftesløshed (asteni) </li>
<li>Vægttab </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter) 
- Nedsat antal blodplader (mild trombocytopeni) 
- Øget følsomhed særligt i huden, jagende eller dunkende smerter langs en eller flere nerver, 
nerveproblemer i arme eller ben (perifer neuropati) 
- Neglelidelser, alvorlige hudreaktioner 
- Posttraumatisk smerte 
- Psoriasis 
- Betændelse i munden/læberne 
- Unormalt indhold af fedt (lipider) i blodet 
- Betændelse i tyktarmen (colitis) </p>
<p>Sjældne (kan forekomme hos op til 1 ud af 1.000 patienter) 
- Leverbetændelse eller leverskade </p>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data) 
- Respiratorisk hypertension </p>
<p>Børn (10 år og derover) og unge 
Ovenstående bivirkninger gælder også for børn og unge. Følgende yderligere oplysninger er vigtige 
for børn, unge og deres omsorgspersoner: </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 patienter) 
- Betændelse i bugspytkirtlen   </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger via det nationale rapporteringssystem anført i Appendiks V* </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden 
af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store teriflunomide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store teriflunomide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen efter "EXP". Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Teriflunomide Accord indeholder: </p>
<p>Teriflunomide Accord 7 mg filmovertrukne tabletter 
- Aktivt stof: teriflunomid. Hver tablet indeholder 7 mg teriflunomid. 
- Øvrige indholdsstoffer: lactosemonohydrat, majsstivelse, mikrokrystallinsk cellulose, 
natriumstivelsesglycolat, hydroxypropylcellulose, magnesiumstearat, kolloid vandfri silica, 
hypromellose (464), titanidioxid (E171), talkum (E553b), macrogol (E1521), indigo carmine 
aluminum lake (E132) og gul jernoxid (E172).  </p>
<p>Teriflunomide Accord 14 mg filmovertrukne tabletter 
- Aktivt stof: teriflunomid. Hver tablet indeholder 14 mg teriflunomid. 
- Øvrige indholdsstoffer: lactosemonohydrat, majsstivelse, mikrokrystallinsk cellulose, 
natriumstivelsesglycolat, hydroxypropylcellulose, magnesiumstearat, kolloid vandfri silica, 
hypromellose (464), titanidioxid (E171), talkum (E553b), macrogol (E1521), indigo carmine 
aluminum lake (E132).  </p>
<p>Udseende og pakningsstørrelser </p>
<p>Teriflunomide Accord 7 mg filmovertrukne tabletter 
Teriflunomide Accord 7 mg filmovertrukne tabletter er lyse grønlig-blålige grå til lyse grønlige blå 
sekskantede, filmovertrukne tabletter, præget med “T1" på den ene side og glatte på den anden side. </p>
<p>Teriflunomide Accord fås i æsker med:</p>
<ul>
<li>14, 28, 84 og 98 tabletter i aluminium-aluminium-blister </li>
<li>14×1, 28×1 og 84×1 og 98×1 tabletter i perforerede enkeltdosisblister af aluminium-aluminium </li>
</ul>
<p>Teriflunomide Accord 14 mg filmovertrukne tabletter 
Teriflunomide Accord 14 mg filmovertrukne tabletter (tabletter) er blålige, femkantede, 
filmovertrukne tabletter, præget med "T2" på den ene side og glatte på den anden side. </p>
<p>Teriflunomide Accord fås i æsker med:</p>
<ul>
<li>28 og 84 tabletter i aluminium-aluminium blister </li>
<li>28×1 og 84×1 tablet i perforeret enkeltdosisblister af aluminium-aluminium </li>
</ul>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført.  </p>
<p>Indehaveren af markedsføringstilladelsen 
Accord Healthcare S.L.U. 
World Trade Center,<br />
Moll De Barcelona s/n,<br />
Edifici Est, 6a Planta,<br />
Barcelona, 08039, Spanien </p>
<p>Fremstiller 
Accord Healthcare Polska Sp. z.o.o. 
ul.Lutomierska 50, 
95-200, Pabianice, Polen </p>
<p>Accord Healthcare B.V. 
Winthontlaan 200,<br />
3526 KV Utrecht, Holland </p>
<p>Pharmadox Healthcare Ltd. 
KW20A Kordin Industrial Park, 
Paola PLA 3000, Malta </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>AT / BE / BG / CY / CZ / DE / DK / EE / ES / FI / FR / GB / HR / HU / IE / IS / IT / LT / LU / LV / 
MT / NL / NO / PL / PT / RO / SE / SI / SK </p>
<p>Accord Healthcare S.L.U. 
Tel: +34 93 301 00<br />
EL 
Win Medica Α.Ε. 
Τηλ: +30 210 74 88<br />
Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-5c60b262e52a5c74cf3187377ecaedde
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for teriflunomide Package Leaflet for language en"
Description: "ePI document Bundle for teriflunomide Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-5c60b262e52a5c74cf3187377ecaedde"
* entry[0].resource = composition-en-5c60b262e52a5c74cf3187377ecaedde

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp5c60b262e52a5c74cf3187377ecaedde"
* entry[=].resource = mp5c60b262e52a5c74cf3187377ecaedde
                            
                    
Instance: bundlepackageleaflet-da-5c60b262e52a5c74cf3187377ecaedde
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for teriflunomide Package Leaflet for language da"
Description: "ePI document Bundle for teriflunomide Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-5c60b262e52a5c74cf3187377ecaedde"
* entry[0].resource = composition-da-5c60b262e52a5c74cf3187377ecaedde

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp5c60b262e52a5c74cf3187377ecaedde"
* entry[=].resource = mp5c60b262e52a5c74cf3187377ecaedde
                            
                    



Instance: mp5c60b262e52a5c74cf3187377ecaedde
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Teriflunomide Accord 14 mg film-coated tablets"
Description: "Teriflunomide Accord 14 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1693/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Teriflunomide Accord 14 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 5c60b262e52a5c74cf3187377ecaeddeListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "teriflunomide"

* status = #current
* mode = #working

* title = "List of all ePIs associated with teriflunomide"

* subject = Reference(mpa06655ee7cdbd14126a29be1f113931d)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#teriflunomide "teriflunomide"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-5c60b262e52a5c74cf3187377ecaedde) // teriflunomide en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-5c60b262e52a5c74cf3187377ecaedde) // teriflunomide da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-5c60b262e52a5c74cf3187377ecaedde
InstanceOf: List

* insert 5c60b262e52a5c74cf3187377ecaeddeListRuleset
    